To date, Vivacelle Bio has been awarded $5.3 million (USD) dollars from the Department of Defense issued on behalf of the Naval Medical Research Center (NMRC) under Medical Technology Enterprise Consortium (MTEC) and the foregoing $251,883.00 NIH Grant. #grants

Vivacelle Bio Awarded an NIH Grant Currently, there is no highly effective treatment for the hypotension and hypovolemia of late septic shock. #grants

Vivacelle Bio has been awarded a $251,883.00 NIH Grant through its Small Business Innovative Research (SBIR) to develop a novel resuscitation fluid based on nano-colloid technology capable of potentially treating the hypotension and hypovolemia of refractory septic shock. #grants

Septic Shock Market is Expected to Expand at a Healthy Growth Rate by (2022-2032), States “Septic Shock Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Septic Shock, digitaljournal.com #septicshock #shockmarket #insight

(BPRW) Vivacelle Bio Announces Early Results of its Phase IIa Clinical Trial of VBI-S for Improving Hypovolemia Due to Sepsis | Black PR Wire, Inc. (Black PR Wire) Kansas City, MO - blackprwire.com vivacellebio#Phase IIa Clinical Trial#

A clinical stage biotechnology company focused on creating products that utilize nanoparticle technology. vivacellebio.com

businesswire.com/news/home/2023… #VBendpoints

Hypovolemic Shock Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - Pharmazz, Perfusion Medical, Vivacelle Bio The Hypovolemic Shock market is expected openpr.com/news/2920693/h… #growth

prnewswire.com/news-releases/…

Vivacelle Bio and University of Missouri-Kansas City School of Medicine Announce Groundbreaking Results from Phase 2a Clinical Trial of VBI-S for Refractory Hypotension in Severe Septic Shock Patients prnewswire.com/news-releases/…

prnewswire.com/news-releases/… groundbreaking#results#

prnewswire.com/news-releases/… saharan#africa#strategy#

prnewswire.com/news-releases/… groundbreaking#results#phase2a#

prnewswire.com Vivacelle Bio's President and Chief Innovation Officer to Present Data Highlighting the Company's Late-Stage Clinical Programs at the BIO International Convention 2024

Vivacelle Bio Initiates Phase 3 Trial for Lead Asset VBI-S to Treat Patients with Hypovolemia Due to Septic Shock prnewswire.com/news-releases/…

Surge in Septic Shock Care: Vivacelle’s Innovative Approach clinicaltrialvanguard.com/executiveinter…

Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia Due to Septic Shock for Phospholipid Nanoparticle-Based VBI-S prnewswire.com/news-releases/…

Empowered Patient Podcast with Dr. Harven DeShield Treating Septic Shock with Nanoparticle Formulation that Redistributes Nitric Oxide with Dr. Harven DeShield - Vivacelle Bio on the Empowered Patient Podcast with Karen Jagoda empoweredpatientradio.com/treating-septi…

Vivacelle Bio Commemorates Sepsis Awareness Month, Recognizing the Leading Cause of Death in U.S. Hospitals prnewswire.com/news-releases/…

Vivacelle Bio to Participate in BIO Partnering @ JPM Week 2025. l Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced its participation in BIO Partnering @ JPM Week 2025 in San Francisco on January 13-16.